Sanofi (SNY) Fell on Tariff Uncertainty

Core Viewpoint - Ariel Investments' "Ariel Global Fund" reported a +7.38% return in Q2 2025, underperforming compared to the MSCI ACWI Index (+11.53%) and MSCI ACWI Value Index (+5.84%) [1] Group 1: Fund Performance - The second quarter of 2025 was marked by volatility, with stocks initially falling after the "Liberation Day" tariff announcement and then rebounding due to a pause in tariff implementation [1] - Enthusiasm for AI-themed stocks and strong corporate earnings contributed to new highs in global and U.S. indices [1] Group 2: Sanofi (NASDAQ:SNY) Analysis - Sanofi's stock experienced a one-month return of -7.26% and a 52-week decline of 18.46%, closing at $46.86 with a market capitalization of $114.201 billion on September 16, 2025 [2] - Concerns over potential U.S. tariffs on European pharmaceutical imports and mixed results from Phase 3 trials of Itepekimab negatively impacted Sanofi's performance [3] - Despite challenges, the company’s immunology pipeline is viewed as undervalued, with optimism surrounding the growth of Dupixent and upcoming Phase 3 outcomes for Amlitelimab [3] Group 3: Hedge Fund Interest - Sanofi was held by 24 hedge fund portfolios at the end of Q2 2025, a decrease from 27 in the previous quarter [4] - While Sanofi is recognized for its potential, certain AI stocks are considered to offer greater upside potential with less downside risk [4]